Insulin resistance plays a significant role in liver fibrosis in chronic hepatitis C and in the response to antiviral therapy

American Journal of Gastroenterology

Volumn 100, Issue 7, 2005, Pages 1509-1515

  D'Souza, Raymond ^a,c   Sabin, C A ^b   Foster, G R ^a  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^b ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^c Paediatric Gastroenterology   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; ASPARTATE AMINOTRANSFERASE; GLUCOSE; INSULIN; PEGINTERFERON ALPHA2A; RIBAVIRIN;

ADULT; ARTICLE; ASIAN; CAUCASIAN; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG HYPERSENSITIVITY; ETHNOLOGY; FEMALE; GENOTYPE; GLUCOSE BLOOD LEVEL; HEPATITIS C; HOMEOSTASIS; HUMAN; INSULIN RESISTANCE; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; TREATMENT OUTCOME;

EID: 22744435914     PISSN: 00029270     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1572-0241.2005.41403.x     Document Type: Article

References (37)

1. WHO. Global surveillance and control of hepatitis C. J Viral Hepat 1999;6:35-47.
2. Alexander G. An association between hepatitis C virus infection and type 2 diabetes mellitus: What is the connection? Ann Intern Med 2000;133(8):650-2.
3. Allison M, Wreghitt T, Palmer C, et al. Evidence for a link between hepatitis C virus infection and diabetes mellitus in a cirrhotic population. J Hepatol 1994;21:1135-9.
4. Mehta S, Brancati F, Sulkowski M, et al. Prevalence of type 2 diabetes mellitus among persons with hepatitis C virus infection in the United States. Ann Intern Med 2000;133:592-9.
5. Knobler H, Schihmanter R, Zifroni A, et al. Increased risk of type 2 diabetes in noncirrhotic patients with chronic hepatitis C virus infection. Mayo Clin Proc 2000;75:355-9.
6. Hui J, Sud A, Farrell G, et al. Insulin resistance is associated with chronic hepatitis C and virus infection fibrosis progression. Gastroenterology 2003;125:1695-704.
7. Furantani M, Nakashima T, Sumida Y, et al. Insulin resistance/ beta-cell function and serum ferritin level in non-diabetic patients with hepatitis C virus infection. Liver Int 2003;23(4):294-9.
8. Ishak K, Bapista A, Bianchi L, et al. Histological grading and staging of chronic hepatitis. J Hepatol 1995;22:696-9.
9. American Diabetes Association. Consensus development conference on insulin resistance. Diabetes Care 1998;21:310-4.
10. Emoto M, Nishizawa Y, Maekawa K, et al. Homeostasis model assessment as a clinical index of insulin resistance in type 2 diabetic patients treated with sulfonylureas. Diabetes Care 1999;22:818-22.
11. Bonora E, Targher G, Alberiche M, et al. Homeostasis model assessment closely mirrors the glucose clamp technique in the assessment of insulin sensitivity: Studies in subjects with various degrees of glucose tolerance and insulin sensitivity. Diabetes Care 2000;23:57-63.
12. Monto A, Alonzo J, Watson J, et al. Steatosis in chronic hepatitis C: Relative contributions of obesity, diabetes mellitus, and alcohol. Hepatology 2002;36:729-36.
13. Ortiz V, Berenguer M, Rayon J, et al. Contribution of obesity to hepatitis C-related fibrosis progression. Am J Gastroenterol 2002;97:2408-14.
14. Cahill G. Beta-cell deficiency, insulin resistance, or both? N Engl J Med 1988;318:1268-70.
15. Reaven G, Bernstein R, Davis B, et al. Nonketotic diabetes mellitus: Insulin deficiency or insulin resistance? Am J Med 1976;60:80-8.
16. Martin B, Warram J, Krolewski A, et al. Role of glucose and insulin resistance in development of type 2 diabetes mellitus: Results of a 25-year follow-up study. Lancet 1992;340:925-9.
17. Warram J, Martin B, Krolewski A, et al. Slow glucose removal and hyperinsulinaemia precede the development of type II diabetes in the offspring of diabetic patients. Ann Intern Med 1990;113:909-15.
18. Monto A, Alonzo J, Watson J, et al. Steatosis in chronic hepatitis C: Relative contributions of obesity, diabetes mellitus, and alcohol. Hepatology 2002;36:729-36.
19. Kumar D, Farrell G, Fung C, et al. Hepatitis C virus genotype 3 is cytopathic to hepatocytes. Genotype-specific reversal of hepatic steatosis after sustained response to antiviral therapy. Hepatology 2002;36:1266-72.
20. Bajaj M, Banerji M. Type 2 diabetics in South Asians: A pathophysiologic focus on Asian-Indian epidemic. Curr Diabetes Rep 2004;43:213-8.
21. Nguyen M, Keefe E. Chronic hepatitis B and hepatitis C in Asian Americans. Rev Gastroenterol Disord 2003;33:125-33.
22. Ram N. Obesity: Preventing and managing the global epidemic: WHO technical report series no 894, World Health Organisation, Geneva (2000).
23. WHO expert consultation: Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies. Lancet 2004;363:157-63.
24. Shintani Y, Fujie H, Miyoshi H, et al. Hepatitis C virus infection and diabetes: Direct involvement of the virus in the development of insulin resistance. Gastroenterology 2004;126:840-8.
25. Aytug S, Reich D, Sapiro L, et al. Impaired IRS-1/P13-kinase signaling in patients with HCV: A mechanism for increased prevalence of type 2 diabetes. Hepatology 2003;38:1384-92.
26. Svegliati-Baroni G, Ridolfi F, Di Sario A, et al. Insulin and insulin-like growth factor-1 stimulate proliferation and type 1 collagen accumulation by human hepatic stellate cells: Differential effects on signal transduction pathways. Hepatology 1999;29:1743-51.
27. Knobler H, Zhornicky T, Sandler A, et al. Tumour necrosis factor-alpha-induced insulin resistance may mediate the hepatitis C virus-diabetes association. Am J Gastroenterol 2003;98(12):2751-6.
28. Maeno T, Okumura A, Ishikawa T, et al. Mechanisms of increased insulin resistance in non-cirrhotic patients with chronic hepatitis C virus infection. J Gastroenterol Hepatol 2003;18(12):1358-63.
29. Paradis V, Dargere D, Vidaud M, et al. Expression of connective tissue growth factor in experimental rat and human liver fibrosis. Hepatology 1999;30:968-76.
30. Manns M, McHutchinson J. Gordon S, et al. Peginterferon a2b plus ribavirin compared to interferon α2b plus ribavirin for the treatment of chronic hepatitis C: A randomized trial. Lancet 2001;358:958-65.
31. Fried M, Schiffman M, Reddy K, et al. Peginterferon a 2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002;347(13):975-82.
32. Alcohol Concern. Proposals for a national strategy for England. London: Alcohol Concern, 1999.
33. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 2004;27:5-10.
34. Hickman I, Powell E, Prins J, et al. In overweight patients with chronic hepatitis C, circulating insulin is associated with hepatic fibrosis: Implications for therapy. J Hepatol 2003;39(6):1042-8.
35. Lecube A, Hernandez C, Genesca J, et al. Diabetes is the main factor for the high ferritin levels detected in chronic hepatitis C virus infection. Diabetes Care 2004; 27(11):2669-75.
36. Furanatani M, Nakashima T, Sumida Y, et al. Insulin resistance/beta-cell function and serum ferritin level in non-diabetic patients with hepatitis C virus infection. Liver Int 2003;23(4):294-9.
37. Hourigan L, MacDonald G, Purdie D, et al. Fibrosis in chronic hepatitis C correlates significantly with body mass index and steatosis. Hepatology 1999;29:1215-9.